Engineered Alpha-Galactosidase Variants for Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, are inadequate due to enzyme instability in blood and lysosomes, poor uptake by target organs, and severe allergic reactions, failing to completely relieve symptoms like neuropathic pain and ischemic attacks.
Innovation Solution
Engineered human alpha-galactosidase polypeptides optimized for improved thermostability, serum stability, reduced immunogenicity, and enhanced cellular uptake, designed to effectively clear globotriaosylceramide from cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If enzyme replacement therapy is used to treat Fabry disease, then globotriaosylceramide clearance is improved, but enzyme stability in blood and lysosomes deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues at specific positions (e.g., E48D, Q68E, D130E, D151L, D202N, D282N, N305G, F365V, L398A) to alter the enzyme's physical and chemical properties. These mutations enhance thermostability, serum stability, and lysosomal stability while maintaining catalytic activity for globotriaosylceramide clearance.
Solution Approach 2:
The patent creates composite enzyme structures by combining wild-type alpha-galactosidase A with engineered mutations. The resulting chimeric enzymes integrate stable structural domains with catalytically active regions, achieving both stability and functionality.
2Productivity
If enzyme replacement therapy is administered, then globotriaosylceramide clearance is improved, but immunogenicity increases causing severe allergic reactions
Solution Approach 1:
The patent modifies immunogenic parameters by introducing specific amino acid substitutions that reduce the immune system's recognition of the enzyme as foreign. These changes decrease antibody formation and allergic reactions while preserving therapeutic efficacy.
3Ease of operation
If standard enzyme therapy is used, then treatment of Fabry disease is provided, but cellular uptake by target organs is poor
Solution Approach 1:
The patent optimizes cellular uptake parameters by engineering surface properties and structural features of the enzyme that enhance recognition and internalization by target organ cells. These modifications improve delivery to lysosomes in affected tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered enzymes exhibit increased stability in blood and lysosomal environments, improved cellular uptake, and reduced immunogenicity, offering more effective treatment of Fabry disease with fewer side effects.
Implementation Method 1
Human alpha galactosidase ('GLA'; EC 3.2.1.22) is a lysosomal glycoprotein responsible for hydrolyzing terminal alpha galactosyl moieties from glycolipids and glycoproteins.
Data Source
AI summary
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.